MedPath

Dyne-101

Generic Name
Dyne-101

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Phase 1
Recruiting
Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
Drug: Placebo
First Posted Date
2022-08-01
Last Posted Date
2025-03-21
Lead Sponsor
Dyne Therapeutics
Target Recruit Count
72
Registration Number
NCT05481879
Locations
🇫🇷

Institut de Myologie, Paris, France

🇩🇪

Ludwig Maximilians University, Munich - Friedrich Baur Institut, Munich, Germany

🇮🇹

Centro Clinico Nemo, Milan, Italy

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath